GlassScriptPhysician profile
Christopher S Mcelroy
NPI 1346343134
$36,723.38
in general payments reported to CMS, 2019-2025
61 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $7,414 · 2021: $2,333 · 2022: $1,789 · 2023: $1,759 · 2024: $2,382 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,423 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,423.18 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,217.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $6,461.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $3,779.25 | 2019-2022 | |
| Novo Nordisk INC | $2,759.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Vascular, INC. | $2,577.52 | 2019 | |
| Amgen INC. | $1,309.25 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $1,056.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $828.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $620.02 | 2021-2025 | |
| Lilly USA, LLC | $571.34 | 2019-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $531.53 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $453.17 | 2019-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.34 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $437.85 | 2019-2021 | |
| Pfizer INC. | $420.49 | 2019-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.